Frank Karbe
Director/Board Member bij PHATHOM PHARMACEUTICALS, INC.
Vermogen: 102 951 $ op 31-03-2024
Profiel
Frank L.
Karbe is currently serving as a Director at Navigen, Inc. and as an Independent Director at Phathom Pharmaceuticals, Inc. He previously held positions as the President, Chief Executive Officer & Director at Better Therapeutics, Inc., an Independent Director at Arbutus Biopharma Corp., an Independent Director at Aduro BioTech, Inc., a Director at Kolltan Pharmaceuticals, Inc., the Chief Financial Officer & Executive Vice President at Exelixis, Inc., and a Vice President-Healthcare Group at Goldman Sachs & Co. LLC.
Additionally, he served as the President at Myovant Sciences, Inc. and The Color Run LLC, and as the Chief Financial Officer at Myovant Sciences Ltd.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 25-05-2023 | 9 000 ( 0.02% ) | 95 580 $ | 31-03-2024 | |
| 18-12-2023 | 526 516 ( 0.97% ) | 7 371 $ | 31-03-2024 |
Actieve functies van Frank Karbe
| Bedrijven | Functie | Begin |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Director/Board Member | 25-04-2022 |
Navigen, Inc.
 Navigen, Inc. Pharmaceuticals: MajorHealth Technology Navigen, Inc. operates as a drug discovery and development company. The company was founded by Hunter Jackson and is headquartered in Salt Lake City, UT. | Director/Board Member | - |
Eerdere bekende functies van Frank Karbe
| Bedrijven | Functie | Einde |
|---|---|---|
| BETTER THERAPEUTICS, INC. | Chief Executive Officer | 14-03-2024 |
Myovant Sciences, Inc.
 Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | President | 12-08-2021 |
| MYOVANT SCIENCES LTD. | Director of Finance/CFO | 12-08-2021 |
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | 05-10-2020 |
| ARBUTUS BIOPHARMA CORPORATION | Director/Board Member | 01-01-2018 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| PHATHOM PHARMACEUTICALS, INC. | Health Technology |
| BETTER THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Kolltan Pharmaceuticals, Inc.
 Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Health Technology |
Goldman Sachs & Co. LLC
 Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Finance |
Navigen, Inc.
Navigen, Inc. Pharmaceuticals: MajorHealth Technology Navigen, Inc. operates as a drug discovery and development company. The company was founded by Hunter Jackson and is headquartered in Salt Lake City, UT. | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Health Technology |
The Color Run LLC
 The Color Run LLC Movies/EntertainmentConsumer Services The Color Run LLC hosts 5K runs in various cities that are not timed, do not have winners, and where participants are doused from head to toe with different color paint at each mile marker. The company was founded by Travis Snyder in 2011 and is headquartered in Salt Lake City, UT. | Consumer Services |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
